Blackfriday

🎉 50% OFF on Membership Fees,
- FOR LIFE! Signup Now!
50% OFF Membership Fees - FOREVER
50 memberships

SOLD OUT

Emergency
Login
🇬🇧 English
 
← Back to Insight

Tomorrow Bio

Tomorrow Bio
|
January 31, 2023
2024

The State of Human Biostasis 2023

Tomorrow Bio's founder and CEO Dr. Emil Kendziorra reviews the state of cryonics (aka Biostasis) in 2022 & 2023
Dr. Emil Kendziorra
Tomorrow Bio
|
October 4, 2022
2024

What Technology Does Tomorrow Bio Use?

Get insight on technology Tomorrow Bio uses for cryopreservation.
Philip Geiblinger
Tomorrow Bio
|
August 12, 2022
2024

A Timeline of Tomorrow Bio Since Inception

Retrace the steps of Tomorrow Bio from inception until today.
Philip Geiblinger
Tomorrow Bio
|
August 8, 2022
2024

Who Is Irishikesh "Rishi" Santhosh?

Uncover the life story of Irishikesh "Rishi" Santhosh, doctor and medical researcher at Tomorrow.Bio
Philip Geiblinger
Tomorrow Bio
|
July 26, 2022
2024

Who Is Fernando Azevedo Pinheiro?

Get some personal insight into the life of Tomorrow's co-founder - Fernando Azevedo Pinheiro.
Philip Geiblinger
Tomorrow Bio
|
July 26, 2022
2024

Who Is Dr. Emil Kendziorra?

Learn more about the man behind Tomorrow.Bio - Dr. Emil Kendziorra.
Philip Geiblinger
The latest on cryonics,
delivered each week
Thank you! Your submission has been received!
Oops! Something went wrong while submitting the form.
Get started today
Sign up nowFree consultation
Cryopreservation
Introduction to cryopreservationCryonics provider comparisonInsight
Plans
Human cryopreservationPet cryopreservationLong-term storagePrice breakdownGeographic coverage
About us
Our storyOur structureMeet the teamTestimonialsMedia appearancesR&D roadmapData & resources
Other
Contact usCareers
Disclaimer: Cryopreservation / Biostasis only provides a chance for a potential future revival, but no one can guarantee if and when such technology will be available in the future.
© 2025 Tomorrow Biostasis GmbH
ImprintCookie policyTerms of usePrivacy policy

Are you visiting from the U.S.?

We’ve detected that you're accessing this site from the U.S. Would you prefer to visit the U.S. version of our website for region-specific content?